Today, a synthetically produced ingredient that mimics the activity of a polypeptide that is found in snake venom is readily available in the marketplace. Among the earliest recorded uses of snakes in Chinese medicine was the application of snake skin in the treatment of superficial diseases, including skin eruptions described in the Shen Nong Ben Cao Jing (ca. AD 100). Modern records indicate that snake venom was used to treat pain and arthritic conditions as early as 1837. It wasn’t until 1949 when Bill Haast established the Miami Serpentarium and became world famous for his dedicated work in conducting self-inflicted studies to try to establish a true medical connection with venomous snakes.
Together with Murray Sanders, PhD, from the University of Miami’s Department of Microbiology, they eventually developed a treatment for polio. Sanders went on to become a Nobel Prize nominee and received several patents for neurotoxins based on snake venom. Research studies on venomous neurotoxins continue in the areas of pain management, breast cancer treatments, Lou Gehrig’s Disease and hematology.
Synthetic Venom Used Today
Pentapharm, a Swiss pharmaceutical company with more than 50 years of experience, is the manufacturer of SYN-AKE, a topical synthetic tripeptide derivative. According to the company, “SYN-AKE is a small peptide that mimics the activity of waglerin 1, a polypeptide that is found in the venom of the Temple Viper, Tropidolaemus wagleri. Clinical trials have shown that SYN-AKE is capable of reducing mimic wrinkles by inhibiting muscle contractions.” Pentapharm conducted in vivo testing with 4% SYN-AKE using 45 volunteers for 28 days, applying the product two times a day. Forehead wrinkles were reduced up to 52% and crow’s-feet were reduced up to 37%. It also showed a reduction in the frequency of contractions of innervated muscle cells by 82% after only two hours of treatment and remained 67% lower two days after treatment. The INCI name is dipeptide diaminobutyroyl benzylamide diacetate (DDBD).